Back to Search
Start Over
Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation
- Source :
- International Journal of Hematology. 97:765-772
- Publication Year :
- 2013
- Publisher :
- Springer Science and Business Media LLC, 2013.
-
Abstract
- Administration of bisphosphonates (BPs) is an essential supportive treatment for reducing bone-related complications in cancer. Deterioration of renal function is one possible side effect of BPs as well as a clinical feature in multiple myeloma. It has been suggested that the nephrotoxicity of different BPs may differ. We performed a retrospective evaluation of renal function in 201 myeloma patients undergoing myeloablative chemotherapy and treatment with ibandronate (I), pamidronate (P), or zoledronate (Z) for up to 36 months. There was no significant deterioration in mean creatinine clearance (CreaCl) in the entire cohort. The percentage of patients experiencing a decrease in CreaCl ≥ 25 % from baseline was 33.0 % in the I group, 44.4 % in the P group and 21.4 % in the Z group, respectively. CreaCl at baseline (P
- Subjects :
- Adult
medicine.medical_specialty
Time Factors
Side effect
medicine.medical_treatment
Urology
Renal function
Hematopoietic stem cell transplantation
Kidney
Kidney Function Tests
urologic and male genital diseases
Nephrotoxicity
Internal medicine
medicine
Humans
Multiple myeloma
Aged
Retrospective Studies
Hematology
Bone Density Conservation Agents
Diphosphonates
business.industry
Remission Induction
Hematopoietic Stem Cell Transplantation
Retrospective cohort study
Middle Aged
medicine.disease
Surgery
Transplantation
Treatment Outcome
Creatinine
Multiple Myeloma
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 18653774 and 09255710
- Volume :
- 97
- Database :
- OpenAIRE
- Journal :
- International Journal of Hematology
- Accession number :
- edsair.doi.dedup.....cc3a04acb41cfebbc32e304c3eac6adf